These conditions can amplify the pro-tumorigenic effects of IL-23 by driving a metabolic shift that supports tumor cell survival and immune tolerance, thereby establishing a feedback loop that perpetuates the inflammatory microenvironment, which in turn promotes tumor growth. The gene discussed is IL37; the disease is neoplasm.